THRA and Alzheimer disease: Recently, the validation of pharmacological CMA activation, achieved through AR7 analogs termed CMA activators (CAs), was observed in vivo across diverse neurodegenerative models including Alzheimer’s disease (AD), as previously discussed [75], and in a mouse model of retinitis pigmentosa [17].